Rifampicin/isoniazid/pyrazinamide

Rifampicin/isoniazid/pyrazinamide
Combination of
Rifampicin Rifamycin antibiotic
Isoniazid First-line anti-tuberculosis medication
Pyrazinamide Anti-tuberculosis medication
Clinical data
Trade names Rifater, Trifazid
AHFS/Drugs.com FDA Professional Drug Information
  • C
  • ℞ (Prescription only)
Oral
Identifiers
J04AM05
PubChem CID 6474062
 Yes (what is this?)  (verify)

Rifampicin/isoniazid/pyrazinamide (trade name Rifater) is a fixed dose combination tablet manufactured by Aventis used in the treatment of tuberculosis. Each tablet contains 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide. It is used in initial treatment of tuberculosis, typically for the first two months.[1][2]

Rifater is contraindicated in children with a body weight of under 40 kg.[2]

The purpose of the fixed dose combination is to make it easier for patients to take their medication; but also to ensure that if patients forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.

See also

References

  1. ↑ Drugs.com: Rifater
  2. ↑ 2.0 2.1 Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.